u/rt_shift_reggie

That is preclinical work and the thread is treating it as a human finding.

What does the wiki page on this say — genuinely asking, not deflecting?

Correcting myself upthread: the criterion I quoted was updated for this year.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

The five things that would have saved me the most time in month one.

One: the first month is a tolerance check, not a results phase. Two: appetite usually changes before the scale does, so watch that instead. Three: write the concentration and the date on the vial the moment you reconstitute anything. Four: the loud posts are not the middle of the distribution. Five: nobody here — including whoever answers most confidently — is your clinician.

None of that is advice about what to take. It is the shape of the first few weeks, which is what I actually wanted and could not find.

Nothing on this board is medical advice, and the people answering you — including me — are members with spreadsheets rather than clinicians.

a press release is not a publication

Concentration is mass over volume, and a U-100 syringe reads 100 units per millilitre.

britta_nakamura has explained this better than the wiki does, which is saying something.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

How long was the randomised phase before any extension?

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

Same. My ICB threshold was different from the neighbouring one and nobody could tell me why.

shortage status changes and the whole arrangement changes with it

That is Scotland’s arrangement and the post is asking about England.

NHS pathway or private prescription?

The two routes, described separately, because mixing them is where most of the confusion here starts.

The NHS route in England runs through specialist weight management services commissioned by your ICB. Criteria, waiting times and what happens at discharge are all local decisions, which is why a confident answer from somebody in a different area may be wrong for you.

The private route is an independent transaction: a consultation, a prescription and a pharmacy price. It does not affect your position on any NHS list and it is not a shortcut through one. Both are legitimate; they are simply not the same pathway and they do not connect.

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

Push back on the advice above: nobody here can tell a member what dose to take, however confidently it is phrased.

Slight disagreement with this bit only, because a beginner reading it might take it as a plan rather than a description.

do not assume the concentration matches the branded product

week two with nothing happening is normal

do not assume the dosing intuitions from the GLP-1 boards transfer

A confidence interval is the range of effects compatible with the data.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

Appetite change and weight change are different measurements on different timescales.

Adding the one habit worth starting today: write the concentration on the vial.

What is the beyond-use date and what is it based on?

Right, and writing the concentration on the vial is the single best habit anyone here can start with.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

EU-wide advice is almost always wrong somewhere

Agreed — and normalising pack size before comparing prices is the fix for half these threads.

The vocabulary, once, since half the questions here are really vocabulary questions.

Titration is stepping the dose up slowly for tolerance. Reconstitution is adding water to a freeze-dried powder. Bacteriostatic water contains a preservative; sterile water does not. COA is a certificate of analysis — a lab document about one batch. Area percent is a purity measure from that document, and it is not the amount of peptide in the vial. Units are a volume on an insulin syringe, not a dose.

That is most of the jargon on this site. The wiki has the longer version of each and it is linked in the sidebar.

phase 2 finds a dose, phase 3 measures the effect

The two routes, described separately, because mixing them is where most of the confusion here starts.

The NHS route in England runs through specialist weight management services commissioned by your ICB. Criteria, waiting times and what happens at discharge are all local decisions, which is why a confident answer from somebody in a different area may be wrong for you.

The private route is an independent transaction: a consultation, a prescription and a pharmacy price. It does not affect your position on any NHS list and it is not a shortcut through one. Both are legitimate; they are simply not the same pathway and they do not connect.

the ICB decides the threshold and they are not the same across England

What week are you in?

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

Is the compound still on the shortage list where you are?

pack sizes differ, so per-month comparisons need care

What is the actual question underneath the question? Happy to answer both.

A supply notice in one member state made the front page here and had no effect at all where I am.

NHS pathway or private prescription?